AL-amyloidosis

AL- amyloidosis is a rare disease that occurs in 30,000 to 45,000 patients in the U.S. and Europe. The patients have a plasma-cell disease including a heterogenous collection of diseases involving protein deposition in one or several organs. The median overall survival is 3.5 years.

Heterogenous diseases with protein deposition

Amyloidosis is a term use for used to describe a highly heterogenous collection of diseases that involve some form of protein deposition in one or several organs. Patients with light chain (AL) amyloidosis suffer from a clonal plasma-cell disease, usually a monoclonal gammopathy of unknown significance (MGUS) or more rarely, myeloma.

Limited treatment options

AL-amyloidosis is a rare disease that occurs in about 30,000 to 45,000 patients in the U.S. and Europe. Current treatment alternatives are limited, and the median overall survival is 3.5 years.